You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 10, 2024

~ Buy the SUSTOL (granisetron) Drug Profile, 2024 PDF Report in the Report Store ~

SUSTOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Sustol patents expire, and when can generic versions of Sustol launch?

Sustol is a drug marketed by Heron Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the granisetron profile page.

DrugPatentWatch® Generic Entry Outlook for Sustol

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for SUSTOL?
  • What are the global sales for SUSTOL?
  • What is Average Wholesale Price for SUSTOL?
Summary for SUSTOL
International Patents:18
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 51
Clinical Trials: 1
Patent Applications: 4,317
Drug Prices: Drug price information for SUSTOL
What excipients (inactive ingredients) are in SUSTOL?SUSTOL excipients list
DailyMed Link:SUSTOL at DailyMed
Drug patent expirations by year for SUSTOL
Drug Prices for SUSTOL

See drug prices for SUSTOL

Recent Clinical Trials for SUSTOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Heron TherapeuticsPhase 4

See all SUSTOL clinical trials

Pharmacology for SUSTOL

US Patents and Regulatory Information for SUSTOL

SUSTOL is protected by five US patents.

Patents protecting SUSTOL

Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY

Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OR PREVENTION OF NAUSEA AND VOMITING

Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SUSTOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 ⤷  Sign Up ⤷  Sign Up
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 ⤷  Sign Up ⤷  Sign Up
Heron Theraps Inc SUSTOL granisetron INJECTABLE;SUBCUTANEOUS 022445-001 Aug 9, 2016 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for SUSTOL

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Kyowa Kirin Holdings B.V. Sancuso granisetron EMEA/H/C/002296
Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.
Authorised no no no 2012-04-20
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for SUSTOL

See the table below for patents covering SUSTOL around the world.

Country Patent Number Title Estimated Expiration
South Korea 20070083851 SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS ⤷  Sign Up
Spain 2529574 ⤷  Sign Up
Japan 2015034182 半固体送達賦形剤および薬学的組成物 (SEMI-SOLID DELIVERY VEHICLE AND PHARMACEUTICAL COMPOSITIONS) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.